Immune-related Gene Methylation Prognostic Instrument for Stratification and Targeted Treatment of Ovarian Cancer Patients Toward Advanced 3PM Approach

Overview

Journal EPMA J

Date 2024 Jun 6

PMID 38841623

Authors

Wenshuang Jia

Na Li

Jingjing Wang

Xiaoxia Gong

Serge Yannick Ouedraogo

Yan Wang

Junkai Zhao

Godfrey Grech

Liang Chen

Xianquan Zhan

Affiliations

Soon will be listed here.

Abstract

Background: DNA methylation is an important mechanism in epigenetics, which can change the transcription ability of genes and is closely related to the pathogenesis of ovarian cancer (OC). We hypothesize that DNA methylation is significantly different in OCs compared to controls. Specific DNA methylation status can be used as a biomarker of OC, and targeted drugs targeting these methylation patterns and DNA methyltransferase may have better therapeutic effects. Studying the key DNA methylation sites of immune-related genes (IRGs) in OC patients and studying the effects of these methylation sites on the immune microenvironment may provide a new method for further exploring the pathogenesis of OC, realizing early detection and effective monitoring of OC, identifying effective biomarkers of DNA methylation subtypes and drug targets, improving the efficacy of targeted drugs or overcoming drug resistance, and better applying it to predictive diagnosis, prevention, and personalized medicine (PPPM; 3PM) of OC.

Method: Hypermethylated subtypes (cluster 1) and hypomethylated subtypes (cluster 2) were established in OCs based on the abundance of different methylation sites in IRGs. The differences in immune score, immune checkpoints, immune cells, and overall survival were analyzed between different methylation subtypes in OC samples. The significant pathways, gene ontology (GO), and protein-protein interaction (PPI) network of the identified methylation sites in IRGs were enriched. In addition, the immune-related methylation signature was constructed with multiple regression analysis. A methylation site model based on IRGs was constructed and verified.

Results: A total of 120 IRGs with 142 differentially methylated sites (DMSs) were identified. The DMSs were clustered into a high-level methylation group (cluster 1) and a low-level methylation group (cluster 2). The significant pathways and GO analysis showed many immune-related and cancer-associated enrichments. A methylation site signature based on IRGs was constructed, including RORC|cg25112191, S100A13|cg14467840, TNF|cg04425624, RLN2|cg03679581, and IL1RL2|cg22797169. The methylation sites of all five genes showed hypomethylation in OC, and there were statistically significant differences among RORC|cg25112191, S100A13|cg14467840, and TNF|cg04425624 ( < 0.05). This prognostic model based on low-level methylation and high-level methylation groups was significantly linked to the immune microenvironment as well as overall survival in OC.

Conclusions: This study provided different methylation subtypes for OC patients according to the methylation sites of IRGs. In addition, it helps establish a relationship between methylation and the immune microenvironment, which showed specific differences in biological signaling pathways, genomic changes, and immune mechanisms within the two subgroups. These data provide ones to deeply understand the mechanism of immune-related methylation genes on the occurrence and development of OC. The methylation-site signature is also to establish new possibilities for OC therapy. These data are a precious resource for stratification and targeted treatment of OC patients toward an advanced 3PM approach.

Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-024-00359-3.

Citing Articles

Multi-omics decipher the immune microenvironment and unveil therapeutic strategies for postoperative ovarian cancer patients.

Liu Z, Wang F, Chen W, Zhai Y, Jian J, Wang X Transl Cancer Res. 2024; 13(11):6028-6044.

PMID: 39697734 PMC: 11651737. DOI: 10.21037/tcr-24-656.

Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches.

Li Z, Li N, Ndzie Noah M, Shao Q, Zhan X EPMA J. 2024; 15(4):711-737.

PMID: 39635022 PMC: 11612093. DOI: 10.1007/s13167-024-00385-1.

Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: subtype classification and prognostic modeling.

Zhang C, Yang J, Chen S, Sun L, Li K, Lai G EPMA J. 2024; 15(3):525-544.

PMID: 39239109 PMC: 11371997. DOI: 10.1007/s13167-024-00374-4.

References

Su H, Lai H, Lin Y, Liu C, Chen C, Chou Y . Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 2009; 127(3):555-67. DOI: 10.1002/ijc.25083. View

Clark S, Harrison J, Molloy P . Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene. 1997; 195(1):67-71. DOI: 10.1016/s0378-1119(97)00164-9. View

Baessler A, Novis C, Shen Z, Perovanovic J, Wadsworth M, Thiede K . Tet2 coordinates with Foxo1 and Runx1 to balance T follicular helper cell and T helper 1 cell differentiation. Sci Adv. 2022; 8(24):eabm4982. PMC: 9200277. DOI: 10.1126/sciadv.abm4982. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J . Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Front Immunol. 2021; 12:768115. PMC: 8710451. DOI: 10.3389/fimmu.2021.768115. View

Li C, Ebert P, Li Q . T cell receptor (TCR) and transforming growth factor β (TGF-β) signaling converge on DNA (cytosine-5)-methyltransferase to control forkhead box protein 3 (foxp3) locus methylation and inducible regulatory T cell differentiation. J Biol Chem. 2013; 288(26):19127-39. PMC: 3696685. DOI: 10.1074/jbc.M113.453357. View

Terp S, Pontoppidan Stoico M, Dybkaer K, Pedersen I . Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clin Epigenetics. 2023; 15(1):24. PMC: 9926627. DOI: 10.1186/s13148-023-01440-w. View

Liu J, Ji C, Wang Y, Zhang C, Zhu H . Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer. Cancer Cell Int. 2021; 21(1):365. PMC: 8272318. DOI: 10.1186/s12935-021-02038-z. View

Mansouri A, Ridgway L, Korapati A, Zhang Q, Tian L, Wang Y . Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003; 278(21):19245-56. DOI: 10.1074/jbc.M208134200. View

10.

Brunckhorst M, Xu Y, Lu R, Yu Q . Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol. 2014; 184(8):2285-96. PMC: 4116697. DOI: 10.1016/j.ajpath.2014.05.006. View

11.

Li Y, Xu J, Chen C, Lu Z, Wan D, Li D . Multimodal epigenetic sequencing analysis (MESA) of cell-free DNA for non-invasive colorectal cancer detection. Genome Med. 2024; 16(1):9. PMC: 10790422. DOI: 10.1186/s13073-023-01280-6. View

12.

Shang A, Wu J, Bi F, Zhang Y, Xu L, Li L . Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. Cancer Biol Ther. 2017; 18(5):314-322. PMC: 5499756. DOI: 10.1080/15384047.2017.1310343. View

13.

Hu J, Xu J, Feng X, Li Y, Hua F, Xu G . Differential Expression of the Gene in Pan-Cancer and Its Related Mechanism. Front Cell Dev Biol. 2021; 9:700661. PMC: 8495169. DOI: 10.3389/fcell.2021.700661. View

14.

Chan D, Lam W, Chen F, Yung M, Chan Y, Chan W . Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clin Epigenetics. 2021; 13(1):142. PMC: 8296615. DOI: 10.1186/s13148-021-01130-5. View

15.

Nan X, Ng H, Johnson C, Laherty C, Turner B, Eisenman R . Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998; 393(6683):386-9. DOI: 10.1038/30764. View

16.

Deng M, Sun J, Xie S, Zhen H, Wang Y, Zhong A . Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Mol Med Rep. 2019; 20(3):2258-2266. PMC: 6691261. DOI: 10.3892/mmr.2019.10477. View

17.

Wang J, Zhang T, Yang L, Yang G . Comprehensive genomic analysis of microenvironment phenotypes in ovarian cancer. PeerJ. 2020; 8:e10255. PMC: 7690309. DOI: 10.7717/peerj.10255. View

18.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou E . RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017; 8(13):21429-21443. PMC: 5400595. DOI: 10.18632/oncotarget.15249. View

19.

Lee S, Adams D, Ipsaro J, Cahn J, Lynn J, Kim H . Chromatin remodeling of histone H3 variants by DDM1 underlies epigenetic inheritance of DNA methylation. Cell. 2023; 186(19):4100-4116.e15. PMC: 10529913. DOI: 10.1016/j.cell.2023.08.001. View

20.

Buttner T, Dietrich D, Zarbl R, Klumper N, Ellinger J, Krausewitz P . Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach. Cancers (Basel). 2024; 16(3). PMC: 10854643. DOI: 10.3390/cancers16030482. View